NEWS

Keep updated on EptivA Therapeutics activities.

Eptiva logo.png
Calcitriol pain.png

EPTIVA THERAPEUTICS ANNOUNCES LICENSING AGREEMENT FOR EXCLUSIVE WORLDWIDE RIGHTS TO CLINICAL STAGE PERSONALIZED ANALGESICS® ASSET

OXFORD, 1st August 2022 — Eptiva Therapeutics Ltd., the first company to apply a precision medicine approach to developing new pain therapeutics, announces today that they have signed a licensing agreement with To Better Days Ltd. for worldwide exclusive rights to develop and commercialize their proprietary transdermal cholecalciferol patch in prescription indications.

Find out more

Bayer eptiva.png

EptivA Therapeutics and Bayer enter into a contract research agreement

EptivA Therapeutics will utilize their proprietary Personalized Analgesics® research platform on Bayer’s research targets.

Find out more

P-375 PT2022 -Mark J .jpg

EptivA Therapeutics  will present at SMi's 22nd Pain Therapeutics Conference in London

EptivA Therapeutics CEO & Founder Mark Field will present at SMi's 22nd Pain Therapeutics Conference in London 4 - 5 May 2022 to discuss Personalized Analgesics® research and how it represents the first precision medicine approach to pain.

Find out more

02

Project Name

More news coming soon....

Press Conference Microphones